388 related articles for article (PubMed ID: 12772186)
1. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
4. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.
Wang W; Zhang X; Mize GJ; Takayama TK
Prostate; 2008 Jul; 68(10):1064-75. PubMed ID: 18386288
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
8. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
9. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
10. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
11. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia.
Castro P; Xia C; Gomez L; Lamb DJ; Ittmann M
Prostate; 2004 Jul; 60(2):153-9. PubMed ID: 15162381
[TBL] [Abstract][Full Text] [Related]
13. Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells.
Kramer G; Steiner GE; Gröbl M; Hrachowitz K; Reithmayr F; Paucz L; Newman M; Madersbacher S; Gruber D; Susani M; Marberger M
Prostate; 2004 Feb; 58(2):109-20. PubMed ID: 14716736
[TBL] [Abstract][Full Text] [Related]
14. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Ishiguro H; Nakaigawa N; Miyoshi Y; Fujinami K; Kubota Y; Uemura H
Prostate; 2005 Jun; 64(1):92-100. PubMed ID: 15666359
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
16. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
17. Expression of ERalpha and ERbeta in prostate cancer.
Linja MJ; Savinainen KJ; Tammela TL; Isola JJ; Visakorpi T
Prostate; 2003 May; 55(3):180-6. PubMed ID: 12692783
[TBL] [Abstract][Full Text] [Related]
18. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
Kramer G; Mitteregger D; Marberger M
Eur Urol; 2007 May; 51(5):1202-16. PubMed ID: 17182170
[TBL] [Abstract][Full Text] [Related]
19. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance.
Di Carlo E; D'Antuono T; Pompa P; Giuliani R; Rosini S; Stuppia L; Musiani P; Sorrentino C
Clin Cancer Res; 2009 May; 15(9):2979-87. PubMed ID: 19366834
[TBL] [Abstract][Full Text] [Related]
20. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines.
Kooijman R; Himpe E; Potikanond S; Coppens A
Growth Horm IGF Res; 2007 Oct; 17(5):383-91. PubMed ID: 17513150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
